Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours

European Journal of Cancer

Volumn 45, Issue 1, 2009, Pages 164-173

  Kalra, Ashish V ^a   Campbell, Robert B ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Anticancer activity; Antitumour; Cancer; Fluorouracil; Human diseases; Mice; Mucin; Mucus overproduction; Pancreatic cancer; Therapeutic mechanism

Indexed keywords

FLUOROURACIL; MUCIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG UPTAKE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; SCID MOUSE; TREATMENT RESPONSE; TUMOR VOLUME;

ACETYLGALACTOSAMINE; ANIMALS; ANTINEOPLASTIC AGENTS; BENZYL COMPOUNDS; CELL LINE, TUMOR; FEMALE; FLUOROURACIL; GLYCOSYLATION; MICE; MUCIN-1; PANCREATIC NEOPLASMS; TREATMENT FAILURE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 57649171078     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.10.008     Document Type: Article

References (34)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Lohr J.M. Medical treatment of pancreatic cancer. Exp Rev Anticancer Ther 7 (2007) 533-544
3. Wang Y., Gao J., Li Z., Jin Z., Gong Y., and Man X. Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profile in endoscopic ultrasound-guided fine-needle aspiration specimens of the pancreas. Int J Cancer 121 (2007) 2716-2722
4. Gendler S.J., and Spicer A.P. Epithelial mucin genes. Ann Rev Physiol 57 (1995) 607-634
5. Andrianifahanana M., Moniaux N., and Batra S.K. Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta 1765 (2006) 189-222
6. Hollingsworth M.A., and Swanson B.J. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4 (2004) 45-60
7. Chambers J.A., and Harris A. Expression of the cystic fibrosis gene and the major pancreatic mucin gene, MUC1, in human ductal epithelial cells. J Cell Sci 105 Pt 2 (1993) 417-422
8. Jass J.R., and Walsh M.D. Altered mucin expression in the gastrointestinal tract: a review. J Cell Mol Med 5 (2001) 327-351
9. Singh P.K., and Hollingsworth M.A. Cell surface-associated mucins in signal transduction. Trends Cell Biol 16 (2006) 467-476
10. Nagata K., Horinouchi M., Saitou M., et al. Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobil Pancreat Surg 14 (2007) 243-254
11. Saitou M., Goto M., Horinouchi M., et al. MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J Clin Pathol 58 (2005) 845-852
12. Kalra A.V., and Campbell R.B. Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain. Brit J Cancer 97 (2007) 910-918
13. Rakha E.A., Boyce R.W., Abd El-Rehim D., et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 18 (2005) 1295-1304
14. Shi Q., and Xie K. Experimental animal models of pancreatic cancer (review). Int J Oncol 17 (2000) 217-225
15. Balkwill F.R., Ward B.G., and Fiers W. Effects of tumour necrosis factor on human tumour xenografts in nude mice. Ciba Found Symp 131 (1987) 154-169
16. Rowlinson-Busza G., Bamias A., Krausz T., and Epenetos A.A. Uptake and distribution of specific and control monoclonal antibodies in subcutaneous xenografts following intratumor injection. Cancer Res 51 (1991) 3251-3256
17. Weckbecker G. Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators. Pharmacol Ther 50 (1991) 367-424
18. Pinedo H.M., and Peters G.F. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6 (1988) 1653-1664
19. Evrard A., Cuq P., Ciccolini J., Vian L., and Cano J.P. Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Brit J Cancer 80 (1999) 1726-1733
20. Fanciullino R., Evrard A., Cuq P., et al. Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: an in-vitro study. Anticancer Drugs 17 (2006) 463-470
21. Song E.Y., Qu C.F., Rizvi S.M., et al. Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model. Cancer Biol Ther 7 (2007)
22. Tarp M.A., and Clausen H. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta 1780 (2008) 546-563
23. Walters R.W., Pilewski J.M., Chiorini J.A., and Zabner J. Secreted and transmembrane mucins inhibit gene transfer with AAV4 more efficiently than AAV5. J Biol Chem 277 (2002) 23709-23713
24. Nagy P., Friedlander E., Tanner M., et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65 (2005) 473-482
25. Hang H.C., and Bertozzi C.R. The chemistry and biology of mucin-type O-linked glycosylation. Bioorg Med Chem 13 (2005) 5021-5034
26. Kalra A.V., and Campbell R.B. Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: implications for tumor vascular targeting. Pharm Res 23 (2006) 2809-2817
27. Tsutsumida H., Swanson B.J., Singh P.K., et al. RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells. Clin Cancer Res 12 (2006) 2976-2987
28. Choi S.R., Cho M., Kim H.R., Ahn D.H., Sleisenger M.H., and Kim Y.S. Biological properties and expression of mucins in 5-fluorouracil resistant HT29 human colon cancer cells. Int J Oncol 17 (2000) 141-147
29. Lesuffleur T., Barbat A., Dussaulx E., and Zweibaum A. Growth adaptation to methotrexate of HT-29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-secreting cells. Cancer Res 50 (1990) 6334-6343
30. Lafitte G., Thuresson K., and Soderman O. Diffusion of nutrients molecules and model drug carriers through mucin layer investigated by magnetic resonance imaging with chemical shift resolution. J Pharm Sci 96 (2007) 258-263
31. Larhed A.W., Artursson P., and Bjork E. The influence of intestinal mucus components on the diffusion of drugs. Pharm Res 15 (1998) 66-71
32. Walter E., Janich S., Roessler B.J., Hilfinger J.M., and Amidon G.L. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J Pharm Sci 85 (1996) 1070-1076
33. Khanvilkar K., Donovan M.D., and Flanagan D.R. Drug transfer through mucus. Adv Drug Delivery Rev 48 (2001) 173-193
34. Meaney C., and O'Driscoll C. Mucus as a barrier to the permeability of hydrophilic and lipophilic compounds in the absence and presence of sodium taurocholate micellar systems using cell culture models. Eur J Pharm Sci 8 (1999) 167-175